3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Mesothelioma
3
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Cholangiocarcinoma
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
12
Nivolumab
4
fludarabine
3
Gemcitabine
3
Drug Therapy
3
Cisplatin
3
spartalizumab
2
budigalimab
2
Injections
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
zenocutuzumab
1
venetoclax
1
ulixertinib
1
tocilizumab
1
tislelizumab
1
seribantumab
1
saracatinib
1
rovalpituzumab tesirine
1
pertuzumab
1
pemigatinib
1
niraparib
1
neratinib
1
milademetan
1
margetuximab
1
erdafitinib
1
entrectinib
1
cobimetinib
1
cediranib
1
bemarituzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
anetumab ravtansine
×
Thoracic
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled